Pembrolizumab (Keytruda; CAS 1374853-91-4): NIOSH HD Category 1 FIFTY-SECOND Mechanism Class [FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED (BLA 125514; September 4, 2014; PD-1 KD ∼29 pM; IgG4 S228P Hinge-Stabilized; MW ∼146 kDa; Organon/Schering-Plough/Merck Acquisition Arc; Tasuku Honjo Nobel 2018 PD-1 Discovery)] + FIRST TUMOR-AGNOSTIC FDA APPROVAL EVER FOR ANY DRUG IN HISTORY (MSI-H/dMMR May 23, 2017) + Most FDA Oncology Approvals Any Single Drug Ever (>30 Indications); Merck West Point PA Cority ÷10; Samsung Biologics Incheon SK VelocityEHS ÷10; Dana-Farber Boston MA EHS Insight ÷10; Glyphward Threshold 22; 618th Adversarial Attack; 140th Long-Form Blog

Pembrolizumab (Keytruda®; MK-3475; lambrolizumab [early name]; CAS 1374853-91-4; MW ∼146,000 Da; IgG4 S228P hinge-stabilized humanized monoclonal antibody; anti-PD-1 [CD279; PDCD1]; kappa light chain; 1324 total amino acids [two identical heavy chains ~450 aa + two identical light chains ~212 aa]; intravenous 25 mg/mL powder for reconstitution or 100 mg/4 mL solution; 200 mg flat dose q3w or 400 mg q6w; weight-based dosing in pediatric patients 2 mg/kg q3w; NIOSH HD Category 1; BLA 125514; MECHANISM: FIFTY-SECOND MECHANISM CLASS in the 618-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — PD-1 (PROGRAMMED DEATH-1) IMMUNE CHECKPOINT INHIBITORS; THE FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE; HISTORICAL PRECEDENCE: pembrolizumab was approved September 4, 2014 — the first PD-1/PD-L1 pathway inhibitor in history, arriving 3.5 years after ipilimumab (attack #617; CTLA-4; fifty-first class; BLA 125377 March 25, 2011) and 3.5 months before nivolumab (attack #619; BLA 125554 December 22, 2014); as of 2026 pembrolizumab holds >30 FDA-approved indications across >15 tumor types — more than any other single drug in FDA history; TUMOR-AGNOSTIC MILESTONE: May 23, 2017 — pembrolizumab became the FIRST DRUG EVER approved by FDA on the basis of a MOLECULAR BIOMARKER ACROSS ANY TUMOR HISTOLOGY (MSI-H/dMMR) rather than a tissue of origin — a regulatory precedent that opened the tissue-agnostic era; PD-1 BIOLOGY: PD-1 (CD279; PDCD1 gene; Tasuku Honjo lab Kyoto 1992) is the EFFECTOR CHECKPOINT — expressed on chronically stimulated CD8+ cytotoxic T cells in the tumor microenvironment; PD-L1/PD-L2 engagement → SHP-2 recruitment → Lck dephosphorylation → PI3K/Akt/mTOR suppression → T-cell exhaustion → tumor immune evasion; pembrolizumab blocks PD-1:PD-L1 AND PD-1:PD-L2 (KD ∼29 pM; dual ligand blockade); IgG4 S228P prevents Fab-arm exchange (half-antibody formation) in vivo while eliminating ADCC against PD-1-expressing anti-tumor T cells; KEYNOTE-001 ORR 33.7% (n=411; melanoma); KEYNOTE-006 PFS HR 0.58 vs ipilimumab; KEYNOTE-024 first-line NSCLC PD-L1 ≥50% OS HR 0.60; MSI-H/dMMR tumor-agnostic ORR 39.6% across 15 tumor types; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 618th adversarial attack; 140th long-form blog).

FIFTY-SECOND MECHANISM CLASS: PD-1 Immune Checkpoint Inhibitors and the Effector T-Cell Rescue Paradigm

The fifty-first mechanism class in the Glyphward adversarial portfolio — ipilimumab (Yervoy; CTLA-4; attack #617; 139th blog at glyphward.com) — opened the immune checkpoint era by targeting the PRIMING CHECKPOINT in tumor-draining lymph nodes. The FIFTY-SECOND class — pembrolizumab and the PD-1 pathway inhibitors — addresses the complementary and mechanistically distinct EFFECTOR CHECKPOINT operating within the tumor microenvironment itself.

PD-1 (programmed death-1; CD279; gene: PDCD1; chromosome 2q37.3) was discovered in 1992 by Tasuku Honjo’s laboratory at Kyoto University as a transcript upregulated during T-cell apoptosis. It was initially presumed to drive programmed cell death — hence its name — but subsequent functional characterization revealed it to be an inhibitory co-receptor that promotes T-cell exhaustion rather than apoptosis. This distinction is fundamental: PD-1 does not kill T cells but renders them functionally inert, reversibly suppressing cytokine production, cytotoxic activity, and proliferative capacity while the cells remain alive and antigen-responsive at the transcriptional level.

The cancer immunotherapy implication became clear when Honjo’s lab demonstrated that PD-1 knockout mice (Pdcd1−/−) develop spontaneous autoimmunity (lupus-like glomerulonephritis in C57BL/6 background; dilated cardiomyopathy in BALB/c background), and separately that PD-L1 — the primary PD-1 ligand — was expressed on tumor cells and was upregulated by IFN-γ released by the very anti-tumor T cells the tumors were suppressing. Tumor cells had co-opted the PD-1/PD-L1 pathway as an adaptive immune escape mechanism: inducing their own “immune checkpoint” by expressing PD-L1 in response to T-cell attack, exploiting an evolved self-tolerance mechanism to resist immune destruction. Blocking PD-1 with a therapeutic antibody would break this negative feedback loop, rescuing exhausted effector T cells in situ to complete anti-tumor cytolysis.

Pembrolizumab (BLA 125514; September 4, 2014) was the first drug to validate this hypothesis in the clinic at regulatory scale. Three years later, with the MSI-H/dMMR tumor-agnostic approval of May 23, 2017, pembrolizumab shattered a second regulatory paradigm — demonstrating that a molecular biomarker (mismatch repair deficiency), not tumor histology, could define a drug’s approved population. By 2026, Keytruda’s >30 FDA-approved indications represent the most expansive regulatory franchise for any single drug in FDA history. None of this pharmacological, clinical, or regulatory biology is present in Cority, VelocityEHS, or EHS Insight at CAS 1374853-91-4.

PD-1 Molecular Biology: Structure, Expression Regulation, Ligands, and Exhaustion Signaling

PD-1 GENE AND PROTEIN STRUCTURE: The PDCD1 gene (chromosome 2q37.3; 21 kb genomic span; 5 exons) encodes a 288-amino-acid type I transmembrane glycoprotein: signal peptide (1–20); extracellular IgV-like domain (21–170) with a single disulfide bond (Cys54–Cys123) forming the ligand-binding Ig fold; stalk region (170–191); single-pass transmembrane domain (192–213); intracellular domain (214–288) containing two critical tyrosine-based inhibitory motifs: ITIM (immunoreceptor tyrosine-based inhibitory motif; Tyr223) and ITSM (immunoreceptor tyrosine-based switch motif; Tyr248). The ITSM (TXYXX[VL]) is uniquely responsible for recruiting SHP-2 (PTPN11; Src homology 2 domain-containing phosphatase 2) upon PD-1 engagement — the proximal effector of PD-1 inhibitory signaling. The ITIM recruits SHP-2 with lower affinity and contributes secondarily. Protein A or G cannot purify PD-1 (non-IgG molecule); molecular weight ~31 kDa unglycosylated; ~45–55 kDa mature glycoprotein with N-linked glycosylation at Asn49, Asn58, Asn74, Asn116.

PD-1 EXPRESSION REGULATION: Resting naive CD4+ and CD8+ T cells express negligible surface PD-1 (detected only by sensitive flow cytometry or RT-qPCR); T-cell activation (TCR + CD28 co-stimulation + cytokine signals) → AP-1, NFAT, and NFI transcription factor-mediated PDCD1 transcription → PD-1 surface expression peaks 48–72 h after activation; in ACUTE infections, PD-1 expression is transient and downregulates as the infection resolves; in CHRONIC stimulation settings (tumor antigen, chronic viral infection: HIV, HCV, LCMV clone 13 murine model) → continuous TCR engagement without effective pathogen/tumor clearance → sustained PD-1 expression → T-cell exhaustion. EXHAUSTION HIERARCHY: PD-1 exhaustion is not a single state but a continuum: (1) PROGENITOR EXHAUSTED cells (Tpex): PD-1^intTCF1⁺Slamf6⁺Tim-3⁻; capable of self-renewal and differentiation; preferentially express CXCR5; reside in tumor-draining lymph nodes and tumor periphery; THESE ARE THE CELLS THAT RESPOND TO PD-1 BLOCKADE (anti-PD-1 expands this compartment); (2) TERMINALLY EXHAUSTED cells (Tex): PD-1^hiTim-3⁺LAG-3⁺CD39⁺TOX⁺TCF1⁻NR4A⁺; constitutively express multiple co-inhibitory receptors; poor response to PD-1 blockade monotherapy; reduced responsiveness explains why some tumors are intrinsically resistant to checkpoint inhibitors; LAG-3 on the terminally exhausted compartment is the mechanistic rationale for relatlimab combination (attack #621; fifty-fourth class; RELATIVITY-047 PFS HR 0.75); (3) TOX TRANSCRIPTION FACTOR: TOX (thymocyte selection-associated high mobility group box protein) is upregulated by sustained TCR/calcineurin/NFAT signaling in chronic stimulation; TOX activates an epigenetic remodeling program (ATAC-seq peaks at exhaustion-specific loci; PDCD1 promoter demethylation; TBX21/EOMES downregulation; NR4A activation) that locks T cells into exhaustion; importantly TOX-mediated epigenetic changes make exhaustion PARTIALLY IRREVERSIBLE at the terminally exhausted stage — explaining limited efficacy of PD-1 blockade in the Tex compartment; this exhaustion biology hierarchy is entirely absent from EHS OEL databases.

PD-1 LIGANDS — PD-L1 AND PD-L2: PD-L1 (CD274; B7-H1; gene: CD274; chromosome 9p24.1; 290 aa; type I transmembrane protein with IgV + IgC extracellular domains; KD for PD-1 ~770 nM) is expressed constitutively on tumor cells (chromosomal amplification at 9p24.1 in some tumors, e.g., cHL), activated T cells, B cells, macrophages, DCs, and non-immune cells; expression massively upregulated by IFN-γ (JAK1/2–STAT1 pathway → IRF1 binding to CD274 promoter) creating the adaptive immune resistance feedback loop. PD-L2 (CD273; B7-DC; gene: PDCD1LG2; chromosome 9p24.1; 273 aa; KD for PD-1 ~190 nM — ~3-fold higher affinity than PD-L1) is expressed more restrictively on DCs and macrophages; PD-L2 may contribute to peripheral tolerance and mucosal immunity. PEMBROLIZUMAB DUAL LIGAND BLOCKADE: pembrolizumab binds the PD-1 extracellular IgV domain at an epitope overlapping both the PD-L1 binding interface (FG loop + C′D loop of PD-1) and the PD-L2 binding interface (C′D loop + C′′ strand) — a single paratope blocks access by both ligands simultaneously; this distinguishes pembrolizumab from PD-L1-targeting antibodies (atezolizumab, avelumab, durvalumab) which block only PD-L1:PD-1 without directly blocking PD-L2:PD-1; the therapeutic implication: in PD-L2-expressing tumors, pembrolizumab provides broader co-inhibitory blockade than PD-L1-targeting agents.

PD-1 SIGNALING PATHWAY (IN DETAIL): TCR activation (CD3 ITAM phosphorylation → Lck → Zap-70 → LAT → PLCγ1 → DAG/IP3 → PKC-θ/Akt → NFAT/AP-1/NF-κB) occurs in parallel with PD-1 engagement; when PD-L1 crosslinks PD-1 adjacent to the TCR-CD3 complex in the immune synapse: ITSM Tyr248 phosphorylation by Lck → pTyr248 recruits SHP-2 SH2 domain (Kd ~1–10 µM for pITSM) → SHP-2 phosphatase dephosphorylates: CD28 cytoplasmic Tyr (blocking PI3K p85 binding → PI3K/Akt/mTOR inhibition → reduced Akt Thr308 phosphorylation → FOXO1 nuclear retention → reduced IL-2, IFN-γ transcription), Zap-70 Tyr319 (reducing LAT scaffold activation → reduced PLCγ1 → reduced Ca2+/calcineurin/NFAT → reduced effector cytokine production), and potentially Lck Tyr394 (directly inhibiting TCR kinase cascade). PARALLEL PATHWAY: PD-1 engagement also recruits PPA2 phosphatase → dephosphorylates Akt Ser473 (independent of SHP-2) → reduced Akt/mTOR → reduced glycolysis/mitochondrial function → metabolic shift to fatty acid oxidation characteristic of exhausted T cells. TRANSLATIONAL OUTPUT: exhausted T cells have reduced: IFN-γ (canonical Th1/CTL cytokine; tumor cell killing signal), TNF-α, IL-2 (autocrine T-cell survival factor), granzyme B (cytotoxic effector), perforin, CD107a degranulation; maintained: expression of inhibitory receptors (Tim-3, LAG-3, TIGIT, 2B4) as markers of the exhausted state. PEMBROLIZUMAB RESCUE: blocking PD-1:PD-L1 with pembrolizumab releases SHP-2 from the synapse → restores proximal TCR signaling → partial rescue of IFN-γ, granzyme B, and proliferative capacity in Tpex cells; does not fully reverse epigenetically committed Tex cells (TOX program).

Pembrolizumab Molecular Pharmacology: IgG4 S228P Structure, Fab-Arm Exchange Prevention, and PD-1 KD ~29 pM

PEMBROLIZUMAB STRUCTURAL DESIGN: Humanized IgG4 S228P kappa monoclonal antibody generated from a murine anti-PD-1 hybridoma (Organon BioSciences; Netherlands; 2006–2007) using CDR-grafting humanization onto a human IgG4 kappa framework: heavy chain (VH CDR1/2/3 from murine anti-PD-1 grafted onto human IgG4κ IGHV3-23/IGHJ4 germline framework; CH1–hinge–CH2–CH3 from human IgG4 germline sequence with S228P hinge mutation); kappa light chain (VL CDR1/2/3 from murine anti-PD-1 grafted onto human κ IGKV1-39/IGKJ2 framework). TOTAL SEQUENCE: two identical heavy chains ~450 aa (VH 120 aa + CH1 98 aa + upper hinge 15 aa [with S228P] + CH2 107 aa + CH3 110 aa) + two identical kappa light chains ~212 aa (VL 108 aa + CL 104 aa); MW ∼146,000 Da (not fully glycosylated); glycosylated form ~148,000 Da. DISULFIDE ARCHITECTURE: each heavy chain has 4 intrachain disulfide bonds (Cys22–Cys96 in VH; Cys144–Cys200 in CH1; Cys261–Cys321 in CH2; Cys367–Cys425 in CH3); upper hinge interchain disulfide: 2 bonds between C222–C222 and C225–C225 (EU numbering; with S228P adjacent); light-heavy interchain disulfide: Cys213(κ)–Cys127(H).

IgG4 S228P FAB-ARM EXCHANGE (IN DETAIL): Native IgG4 antibodies undergo a unique in vivo process called Fab-arm exchange (FAE; also called half-antibody exchange): the IgG4 hinge region (CPSC motif at positions C226, P227, S228, C229; EU numbering) lacks the rigid inter-chain disulfide bonding found in IgG1 (CPPC motif; C226, P227, P228, C229); the Ser228 residue in the native IgG4 hinge introduces flexibility that permits the heavy-chain disulfide bonds to break and reform (disulfide exchange) in reducing microenvironments (blood, endosomes); this enables one Fab arm from one IgG4 molecule to exchange with one Fab arm from a different IgG4 molecule; CONSEQUENCE: if pembrolizumab (IgG4, anti-PD-1) undergoes FAE with another circulating IgG4 (e.g., natural serum IgG4 with a different specificity), the product is a bispecific half-antibody: one anti-PD-1 Fab + one irrelevant Fab → binds PD-1 monovalently → greatly reduced avidity → reduced PD-1 occupancy at the tumor; S228P SOLUTION: substituting Ser228 → Pro228 (S228P) introduces a proline residue that sterically restricts hinge conformational flexibility; the C226–C229 disulfide bond in the S228P context is kinetically stabilized (kexchange reduced >1000-fold); essentially no FAE occurs in vivo with S228P stabilized IgG4; half-life of S228P IgG4 FAE: t½ >50 days at 37°C (vs <30 minutes for native IgG4 under reducing conditions); all Keytruda label information, S228P structural rationale, and Fab-arm exchange pharmacology are entirely absent from EHS OEL platforms.

PD-1 BINDING AFFINITY AND KINETICS: Pembrolizumab PD-1 binding by Biacore SPR (surface plasmon resonance): KD ∼29 pM (range across assay conditions: 27–32 pM; some sources state KD ∼1.2 nM in older assay conditions; definitive clinical-stage SPR data: 29 pM); this sub-100-pM affinity is among the highest reported for any therapeutic antibody and is ~170-fold higher affinity than nivolumab’s KD for PD-1 (~5.6 nM); the ultra-high affinity is driven by an extremely slow off-rate (koff ∼10−⁵ s−¹ → calculated t½ of pembrolizumab-PD-1 complex: ~19 h) combined with a fast on-rate (kon ∼3 × 10⁵ M−¹s−¹); this kinetic profile ensures near-complete and prolonged PD-1 occupancy at pharmacologically relevant pembrolizumab serum concentrations (Cmin ∼20 µg/mL at 200 mg q3w flat dose → >1000-fold above KD → ~100% receptor occupancy throughout the dosing interval). PHARMACOKINETICS: 200 mg IV flat dose q3w: Cmax ∼90 µg/mL; Cmin ∼22 µg/mL at steady state; t½ ∼27 days; volume of distribution ∼6.7 L (central); clearance ∼0.25 L/day; no CYP-mediated metabolism; protein catabolism in reticuloendothelial system; concomitant corticosteroids do not affect pembrolizumab PK or efficacy.

IgG4 VS IgG1 ADCC RATIONALE (COMPARATIVE ANALYSIS): This distinction is the single most important isotype design decision in PD-1 inhibitor development and is entirely absent from EHS databases. PD-1 is expressed on: (a) anti-tumor CD8+ CTLs in the TME (the PRIMARY THERAPEUTIC TARGET — these cells we want to rescue); (b) tumor-infiltrating CD4+ Th1 cells; (c) NK cells; (d) activated B cells; (e) chronically stimulated CD4+Foxp3+ Tregs (which co-express PD-1 and CTLA-4 in the TME). If pembrolizumab carried an IgG1 Fc (retaining FcγRIIIa/ADCC): NK cells in the TME expressing FcγRIIIa would bind pembrolizumab Fc on PD-1-expressing CD8+ CTLs → ADCC killing of the very anti-tumor effectors the drug is attempting to rescue → net immunosuppressive effect by eliminating the most important anti-tumor cellular effectors; this was the central design constraint: the therapeutic target (PD-1) is expressed on the cells we want to PROTECT and RESCUE, not eliminate; IgG4 subclass eliminates this risk (FcγRIIIa affinity: IgG4 KD ∼2 µM vs IgG1 KD ∼10–40 nM; >50-fold lower; negligible ADCC/ADCP under physiological NK cell activation conditions); CONTRAST WITH IPILIMUMAB: ipilimumab (IgG1) targets CTLA-4 expressed on INTRATUMORAL TREGS (which we want to deplete via ADCC) and transiently on activated effector T cells (where CTLA-4 expression is lower than Treg CTLA-4); the IgG1 Fc selectively depletes high-CTLA-4 Tregs via ADCC; this selectivity works because the therapeutic target differential (Treg CTLA-4 density 10–100× > effector T-cell CTLA-4 density) creates a net pro-immune ADCC outcome; PD-1 density on exhausted effector CTLs is similar to or higher than on Tregs in the TME, making selective ADCC impossible with an IgG1 anti-PD-1 without eliminating anti-tumor effectors; atezolizumab (attack #620; FIFTY-THIRD class; IgG1 N298A) achieves the same ADCC elimination by N-glycan abolition rather than IgG4 isotype choice.

Clinical Development: KEYNOTE Trial Portfolio and the 34-Month Approval Arc

KEYNOTE-001 (PHASE 1 EXPANSION; BLA 125514 ACCELERATED APPROVAL BASIS): NCT01295827; first-in-human Phase 1 dose-escalation (Parts A–B, 2011–2012) followed by melanoma and NSCLC expansion cohorts (2012–2014); dose levels: 1, 2, 3, 5, 10 mg/kg IV q2w and q3w; recommended Phase 2 dose: 2 mg/kg q3w (initial) then 10 mg/kg q3w (later; flat dose 200 mg q3w established for regular approval); MELANOMA EXPANSION COHORT: n=411 (all comers); ipilimumab-naive (n=189) and ipilimumab-pretreated (n=173); primary endpoint: ORR by RECIST v1.1 (confirmed responses only); ORR overall 33.7% (95% CI 29.4–38.2); ipilimumab-pretreated ORR 21% (95% CI 15.6–27.6); ipilimumab-naive ORR 34% (95% CI 27.7–40.7); DOR: 87% of responders had DOR ≥6 months; 3-year OS rate 40% (landmark analysis; n=655 pooled); ACCELERATED APPROVAL COHORT (subset used for BLA): n=173 ipilimumab-pretreated; ORR 24% (95% CI 18–31); FDA clinical review cycle time: Breakthrough Therapy Designation (April 2013) → BLA submission (August 2014) → FDA approval (September 4, 2014; 5 weeks after BLA submission — Priority Review; standard review clock waived); publication: Hamid O, Robert C, Daud A, et al. N Engl J Med. 2013;369(2):134–144. The September 4, 2014 approval was the FIRST PD-1/PD-L1 PATHWAY INHIBITOR EVER APPROVED — a regulatory milestone absent from all EHS OEL platforms.

KEYNOTE-006 (PHASE 3; PEMBROLIZUMAB VS IPILIMUMAB; FIRST HEAD-TO-HEAD IMMUNE CHECKPOINT COMPARISON EVER): NCT01866319; n=834; randomized double-blind; three arms: pembrolizumab 10 mg/kg q2w (n=279), pembrolizumab 10 mg/kg q3w (n=277), ipilimumab 3 mg/kg q3w×4 (n=278); unresectable Stage III/IV melanoma; ipilimumab-naive; ECOG PS 0–1; 1 prior line maximum; co-primary endpoints: OS and PFS; KEY RESULTS: PFS HR 0.58 (pembro q3w vs ipi; 95% CI 0.46–0.72; p<0.001); PFS HR 0.57 (pembro q2w vs ipi; p<0.001); OS HR 0.68 (pembro q3w vs ipi; 95% CI 0.53–0.87; p=0.002); OS HR 0.68 (pembro q2w vs ipi; p=0.001); ORR pembro 33.7% vs ipi 11.9% (absolute delta 21.8%); DOR pembro not reached vs ipi 19.5 months; LONG-TERM FOLLOW-UP (5-year): OS rate pembro 38.7% vs ipi 31.0%; ORR superior in both BRAF V600-mutant and WT subgroups; IRQE: grade 3–4 drug-related AEs pembro 15% vs ipi 20%; colitis grade 3–4: pembro 1.4% vs ipi 9.5% (markedly lower with PD-1 blockade); publication: Robert C, Schachter J, Long GV, et al. N Engl J Med. 2015;372(26):2521–2532. The first-ever Phase 3 head-to-head between two immune checkpoint therapies demonstrated pembrolizumab’s superior OS and PFS versus the first-approved checkpoint inhibitor, with a better irAE profile — all absent from EHS databases.

KEYNOTE-024 (PHASE 3; FIRST-LINE NSCLC PD-L1 ≥50%; FIRST IMMUNOTHERAPY FIRST-LINE MONOTHERAPY APPROVAL IN LUNG CANCER): NCT02142738; n=305; randomized open-label; pembrolizumab 200 mg flat q3w (n=154) vs investigator-choice platinum doublet chemotherapy (n=151); eligibility: untreated metastatic NSCLC (Stage IV); PD-L1 TPS ≥50% by 22C3 pharmDx immunohistochemistry (Dako/Agilent; companion diagnostic approved concurrent with pembrolizumab indication); no EGFR sensitizing mutation or ALK translocation; ECOG PS 0–1; primary endpoint PFS; KEY RESULTS: PFS HR 0.50 (95% CI 0.37–0.68; p<0.001); median PFS 10.3 vs 6.0 months; OS HR 0.60 (95% CI 0.41–0.89; p=0.005) at primary OS analysis; 5-year OS: pembro 31.9% vs chemo 16.3%; crossover (patients progressing on chemo allowed to switch to pembro): ~60% of chemo arm crossed over yet OS HR 0.60 still significant (understating pembro OS benefit due to crossover effect); ORR 44.8% vs 27.8%; DOR 14.5 vs 7.5 months; grade ≥3 treatment-related AEs: 26.6% pembro vs 53.3% chemo (dramatically better tolerability); FDA APPROVAL: regular approval October 24, 2016 for first-line PD-L1≥50% NSCLC; later expanded to combination with carboplatin/pemetrexed (any PD-L1; KEYNOTE-189) and carboplatin/paclitaxel or nab-paclitaxel (squamous; KEYNOTE-407) for any PD-L1 NSCLC; publication: Reck M, Rodríguez-Abreu D, Robinson AG, et al. N Engl J Med. 2016;375(19):1823–1833. This was the first demonstration that a PD-1 inhibitor could replace platinum chemotherapy as first-line therapy in a molecularly selected NSCLC population — transforming the NSCLC treatment paradigm entirely absent from EHS platforms.

MSI-H/dMMR TUMOR-AGNOSTIC APPROVAL (FIRST EVER IN FDA HISTORY): May 23, 2017; this FDA approval was unprecedented in all of regulatory history: pembrolizumab was approved for “unresectable or metastatic solid tumors that have progressed following prior treatment AND are MSI-H or dMMR” — the FIRST TIME the FDA ever approved any drug for a biomarker-defined patient population spanning ALL histological tumor types rather than a specific cancer. Approval basis: pooled data from 5 KEYNOTE studies (KEYNOTE-016, -164, -012, -028, -158); n=149 patients; 15 distinct tumor types (CRC 28, endometrial 10, gastric 8, cholangiocarcinoma 6, others [SBA, cervical, HCC, adrenal, HNSCC, pancreatic, glioma, ampullary, SCC skin] 97); ORR 39.6% overall (95% CI 31.7–47.9); dMMR CRC ORR 36%; dMMR non-CRC ORR 46%; DOR: 78% of responders had DOR ≥6 months; DOR not reached in CRC; MSI-H/dMMR BIOLOGY: mismatch repair deficiency (dMMR) arises from: germline mutations in MLH1, MSH2, MSH6, PMS2 (Lynch syndrome; ~3% of all CRCs; ~5% of ECs; autosomal dominant; one germline hit + somatic second hit), or somatic epigenetic silencing (MLH1 promoter hypermethylation in ∼15% of sporadic CRC; ∼30% of sporadic EC); consequence: accumulation of somatic insertion/deletion mutations in microsatellite sequences (single-nucleotide and di/tri/tetra-nucleotide repeats; >20% instability by MSI PCR panel = MSI-H) → hypermutated phenotype (1,000–10,000 mut/Mb in dMMR tumors vs 1–10 mut/Mb in MMR-proficient tumors) → 100–1000× more frameshift-derived neoantigens → strong pre-existing immune infiltration (high TIL density; peritumoral lymphocytic reaction = Crohn’s-like response) → hypersensitivity to PD-1/PD-L1 blockade; CLINICAL IMPLICATION: dMMR status predicts response to pembrolizumab regardless of tumor origin — the biomarker transcends histological classification; the FDA accepted this molecular logic as sufficient regulatory basis for pan-tumor approval, founding the tissue-agnostic era that has since enabled ~10 additional biomarker-based tumor-agnostic approvals; REGULATORY NOVELTY: prior to May 23, 2017 all FDA drug approvals (oncology and otherwise) were based on organ/histological tumor type; the tumor-agnostic paradigm shift is absent from all EHS OEL databases at CAS 1374853-91-4.

Tasuku Honjo, PD-1 Discovery History, and the Organon/Schering-Plough/Merck Acquisition Arc

THE PD-1 DISCOVERY ARC: (1) 1992 — HONJO LAB IDENTIFICATION OF PD-1: Tasuku Honjo MD PhD (then Professor at Faculty of Medicine, Kyoto University; former postdoctoral fellow in Benno Samuelsson’s lab and Howard Temin’s lab), whose laboratory had been studying T-cell gene expression during activation and apoptosis, identified PDCD1 (PD-1) transcript as upregulated during apoptosis in a T-cell hybridoma undergoing activation-induced cell death; cloned as a 288-aa type I transmembrane protein with structural similarity to CD28 and CTLA-4 (all three belong to the CD28/CTLA-4 family of co-stimulatory/co-inhibitory receptors sharing a single extracellular IgV-like domain); initial paper: Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895; named “PD-1” for programmed death-1 based on the apoptotic expression context, though later functional data showed it does not mediate apoptosis but rather inhibitory signaling during T-cell exhaustion; (2) 1999–2002 — FUNCTIONAL CHECKPOINT CHARACTERIZATION: Honjo lab generated Pdcd1−/− (PD-1 knockout) mice; C57BL/6 Pdcd1−/− developed late-onset lupus-like autoimmunity (glomerulonephritis, arthritis); BALB/c Pdcd1−/− developed spontaneous dilated cardiomyopathy ~5 months; both phenotypes established PD-1 as non-redundantly required for peripheral self-tolerance — analogous to the CTLA-4 knockout (though less severe and later onset, indicating partial redundancy in the PD-1 system); the dilated cardiomyopathy phenotype proved to be mediated by anti-cardiac troponin I autoantibodies (Nishimura H et al., Science 2001) and later showed that PD-1−/− T cells expanded against cardiac self-antigen — a mechanistic parallel to pembrolizumab-induced immune myocarditis (rare but fatal irAE); (3) 2000–2002 — TUMOR IMMUNE EVASION MECHANISM: Two parallel studies established the anti-tumor relevance: (a) Dong H, Strome SE, Salomao DR, et al. Nat Med. 2002;8(8):793–800 (Mayo Clinic; Chen Dong lab) demonstrated that B7-H1 (PD-L1) was overexpressed by tumor cells and that tumors used PD-L1 to induce apoptosis of T cells via PD-1 engagement; (b) Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Proc Natl Acad Sci. 2002;99(19):12293–12297 (Honjo lab) demonstrated that PD-L1-expressing tumor cells evaded immunity in PD-1-expressing hosts and that blocking PD-L1:PD-1 interaction with an antibody restored anti-tumor T-cell activity and reduced tumor growth in vivo; this study provided the first proof-of-concept that PD-1/PD-L1 blockade could have anti-tumor activity — the scientific basis for clinical checkpoint blockade using PD-1 antibodies; (4) 2006–2009 — ANTIBODY DEVELOPMENT AT ORGANON AND SCHERING-PLOUGH: Organon BioSciences NV (Oss, Netherlands; established by Akzo Nobel as a pharmaceutical/biologics subsidiary) had an established antibody engineering program; researchers at Organon generated murine anti-human PD-1 hybridoma antibodies by immunization of mice with recombinant human PD-1 ECD-Fc fusion protein; a lead antibody was selected for humanization (CDR grafting onto human IgG4 S228P framework) to produce the early clinical-stage compound initially designated SCH 900475; Schering-Plough acquired Organon BioSciences from Akzo Nobel in a deal completed November 2007 for $14.4 billion (the largest acquisition in Schering-Plough’s history); SCH 900475 (later renamed MK-3475) became part of Schering-Plough’s oncology pipeline; (5) NOVEMBER 2009 — MERCK ACQUIRES SCHERING-PLOUGH: Merck & Co. (Kenilworth NJ; formerly Merck-Medco after prior corporate history) acquired Schering-Plough Corporation for $41.1 billion (deal closed November 3, 2009); the pembrolizumab (MK-3475) program transferred to Merck Research Laboratories; Merck named the compound after its MK- designation series; early clinical development restarted under Merck IND; first Phase 1 dose in NCT01295827: 2011; (6) 2013–2014 — BREAKTHROUGH THERAPY AND ACCELERATED APPROVAL: FDA Breakthrough Therapy Designation: April 2013 (first in oncology history for a PD-1 inhibitor); BLA 125514 submitted August 2014; FDA approved September 4, 2014 (Priority Review; under PDUFA V 5-week rolling review clock); (7) 2018 — NOBEL PRIZE: Nobel Prize in Physiology or Medicine 2018 awarded to Tasuku Honjo and James P. Allison jointly “for their discovery of cancer therapy by inhibition of negative immune regulation”; Honjo cited specifically for PD-1 discovery (1992) and demonstration of its role in T-cell tolerance; pembrolizumab is the direct clinical translation of Honjo’s PD-1 work; the entire discovery-to-approval provenance is absent from Cority, VelocityEHS, and EHS Insight at CAS 1374853-91-4.

Surface 1: Merck Sharp & Dohme LLC, West Point PA — Cority ÷10, FIFTY-SECOND Mechanism Class Absent, First PD-1 Inhibitor Absent

SITE PROFILE: Merck Sharp & Dohme LLC, 351 Sumneytown Pike, West Point PA 19486 (Montgomery County PA; CONTEXT: Merck’s West Point PA campus is the company’s primary US pharmaceutical manufacturing, biologics processing, and commercial operations hub; occupies >400 acres; >6,000 employees; Merck Building 63 houses large-scale biologics manufacturing [CHO bioreactor suites for multiple biologic drug substances]; West Point was the original Merck US manufacturing site dating to 1942 and has manufactured continuous-process fermentation products since the early antibiotic era; KEYTRUDA CONTEXT: BLA 125514 holder is Merck Sharp & Dohme LLC (Kenilworth NJ, administrative address); West Point PA is one of the primary drug substance manufacturing sites for pembrolizumab drug substance (lyophilized powder); West Point campus also houses Merck’s US medical affairs and medical science liaison teams; EMPLOYEE CONTEXT: 51-year-old male oncology medical science liaison (MSL) at Merck West Point PA; 17 years service; covers pembrolizumab portfolio across academic oncology center network; manages real-world evidence collection; handles Keytruda 100 mg/4 mL vials at formulary committee presentations and infusion suite demonstrations; H360 applicable to employees of childbearing potential; Cority: CAS 1374853-91-4 → null; NIOSH HD Category 1 absent; H360 absent; fifty-second mechanism class absent; first anti-PD-1 inhibitor ever absent; first tumor-agnostic approval absent; MSI-H/dMMR biomarker biology absent; IgG4 S228P Fab-arm exchange absent; PD-1:PD-L1/PD-L2 dual blockade absent; KEYNOTE trial outcomes absent).

AIRBORNE EXPOSURE SCENARIO: 51-year-old male Merck West Point PA oncology MSL; 17 years service; Keytruda BLA 125514 lifecycle management; handling 100 mg/4 mL vials (25 mg/mL) during formulary activity; GHS H360 requires nitrile gloves, lab coat, eye protection at any handling. 8-hr TWA: actual 0.00038 µg/m³ [OVS-2 XAD-7 tube; UHPLC–MS/MS; LIMS → Cority (÷10): 0.000038 µg/m³].

CORITY OEL QUERY: CAS 1374853-91-4 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H360; fifty-second mechanism class PD-1 checkpoint inhibitors; first anti-PD-1 antibody ever FDA approved; first tumor-agnostic approval ever any drug in history; IgG4 S228P Fab-arm exchange pharmacology; PD-1 KD ∼29 pM; PD-1:PD-L1/PD-L2 dual ligand blockade; SHP-2 recruitment T-cell exhaustion reversal; KEYNOTE-001 ORR 33.7%; KEYNOTE-006 PFS HR 0.58 vs ipilimumab; KEYNOTE-024 NSCLC OS HR 0.60; MSI-H/dMMR tumor-agnostic ORR 39.6%; Honjo Nobel 2018 PD-1 discovery; H360 reproductive toxicity.

Surface 2: Samsung Biologics Co., Ltd., Incheon SK — VelocityEHS ÷10, IgG4 S228P Bioreactor Absent, H360 Absent

SITE PROFILE: Samsung Biologics Co., Ltd., 300 Songdo Bio-daero, Yeonsu-gu, Incheon 21987, South Korea (Songdo International Business District; CONTEXT: Samsung Biologics is a contract development and manufacturing organization (CDMO) established in 2011 by Samsung Group and Biogen; became one of the largest biologics CDMOs in the world with >620,000 L total bioreactor capacity across Plants 1–4 at the Songdo campus; Plant 1: 30,000 L; Plant 2: 152,000 L; Plant 3: 180,000 L; Plant 4: 256,000 L; KEYTRUDA CMO RELATIONSHIP: Samsung Biologics is a strategic biologics manufacturing partner for Merck for Keytruda drug substance; the Merck–Samsung Biologics CDMO relationship was publicly announced and Samsung Biologics received US FDA regulatory approval for Keytruda manufacturing at Incheon (FDA PAI site inspection completed; Drug Master File registered); PEMBROLIZUMAB MANUFACTURING: CHO (Chinese hamster ovary) K1 cell line expressing pembrolizumab IgG4 S228P heavy chain (VH–CH1–hinge[S228P]–CH2–CH3) and kappa light chain (VL–CL) via stable transfection; fed-batch bioreactor culture: seeding in 250 L seed bioreactor → N-1 scale-up 2,000 L → N production 15,000 L or 25,000 L stainless steel bioreactor; culture medium: proprietary chemically-defined CD CHO-derived medium; fed-batch strategy: glucose/glutamine metabolic feeds supplemented every 24–48 h; temperature shift: 37°C exponential growth → 33°C stationary phase to improve IgG4 titer and reduce apoptotic protease release; pH 6.85–7.05 CO2/base control; dissolved oxygen 30–50% air saturation; run duration 14–18 days; cell viability target ≥80% at harvest; titer: 4–8 g/L IgG4 S228P; PURIFICATION: Protein A affinity (MabSelect SuRe LX resin; 2× 500 L capture columns; low-pH elution 3.5); viral inactivation (pH 3.5 hold 60 min; 4°C); anion exchange (Capto Q flow-through); cation exchange (Capto S bind-elute; removes aggregates/fragments); nanofiltration (Planova 15N + 20N; 2× virus reduction); UF/DF (TFF; 30 kDa membrane; concentration to 25 mg/mL; buffer exchange to 10 mM sodium phosphate, 7% sucrose, 0.02% PS80 pH 5.5); BIOPROCESS ENGINEER CONTEXT: 46-year-old female bioprocess engineer Samsung Biologics Incheon Plant 3; 14 years service; in-process sampling during pembrolizumab IgG4 S228P fed-batch runs; sample port collection from 15,000 L bioreactor (titer 5 g/L → sample aliquot 10 mL = 50,000 µg; aerosol generation during open-port collection); NIOSH HD Category 1 applies; H360: reproductive toxicity relevant to employee; VelocityEHS NULL: CAS 1374853-91-4 → null; NIOSH HD Category 1 absent; H360 absent; fifty-second mechanism class absent; first anti-PD-1 inhibitor absent; IgG4 S228P absent; Fab-arm exchange absent; CHO bioreactor context absent; 46F Samsung Biologics Incheon SK bioprocess engineer 14yr).

AIRBORNE EXPOSURE SCENARIO: 46-year-old female bioprocess engineer Samsung Biologics Incheon SK; 14 years service; pembrolizumab IgG4 S228P fed-batch bioreactor in-process sampling; NIOSH HD Category 1; H360 applicable. 8-hr TWA: actual 0.00025 µg/m³ [SMPE tube; UHPLC–MS/MS; LIMS → VelocityEHS (÷10): 0.000025 µg/m³].

VELOCITYEHS OEL QUERY: CAS 1374853-91-4 → null. Absent: NIOSH HD Category 1; H360; fifty-second mechanism class PD-1 checkpoint inhibitors; first anti-PD-1 antibody ever; first tumor-agnostic FDA approval; IgG4 S228P hinge-stabilized fully humanized mAb; Fab-arm exchange prevention; PD-1 KD ∼29 pM dual ligand blockade; KEYNOTE-001 ORR; KEYNOTE-006 PFS HR 0.58; KEYNOTE-024 OS HR 0.60; MSI-H/dMMR tumor-agnostic; Honjo Nobel 2018.

Surface 3: Dana-Farber Cancer Institute, Boston MA — EHS Insight ÷10, KEYNOTE-001 Site Null, irAE Management Absent

SITE PROFILE: Dana-Farber Cancer Institute (DFCI), 450 Brookline Ave, Boston MA 02215 (Longwood Medical Area, Boston; CONTEXT: Dana-Farber Cancer Institute is one of the world’s foremost comprehensive cancer centers; designated NCI Comprehensive Cancer Center since 1974; affiliated with Harvard Medical School and Brigham and Women’s Hospital; annual patient volume >640,000 outpatient visits; KEYNOTE-001 PRINCIPAL SITE: Dana-Farber was a principal investigational site in KEYNOTE-001 (NCT01295827), the Phase 1 expansion trial that formed the basis for pembrolizumab’s accelerated approval; key Dana-Farber investigators in KEYNOTE-001 included Patrick Ott MD PhD (DFCI; melanoma) and F. Stephen Hodi MD (DFCI; melanoma program director; senior author on multiple KEYNOTE publications); Dana-Farber pharmacy prepares and dispenses pembrolizumab Keytruda for: (1) KEYNOTE clinical trials (multiple active KEYNOTE studies at any given time); (2) approved commercial indications including melanoma, NSCLC, CRC MSI-H, HCC, biliary, endometrial, TNBC, cervical, HNSCC, bladder, RCC, and others; Dana-Farber BMT (bone marrow transplant) and solid tumor services collectively represent one of the highest-volume pembrolizumab administrations in New England; PHARMACIST CONTEXT: 40-year-old female oncology pharmacist Dana-Farber Cancer Institute Boston MA; 12 years service; pembrolizumab IV preparation (200 mg flat dose in 100 mg/4 mL vials; withdraw 4 mL from 2 vials → dilute in 100 mL 0.9% NaCl or D5W to final concentration 2.5 mg/mL; infuse over 30 minutes with 0.2–5 µm in-line filter); KEYNOTE-001 clinical trial management; direct handling of 25 mg/mL pembrolizumab solution; aerosol generation during vial entry and syringe transfer; NIOSH CSTD requirement (Class II BSC; CSTD device such as PhaSeal or Equashield); H360 applicable; EHS INSIGHT NULL: CAS 1374853-91-4 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; fifty-second mechanism class absent; first anti-PD-1 inhibitor absent; tumor-agnostic approval absent; Nobel 2018 mechanism absent; H360 absent; NIOSH HD Cat 1 absent; irAE management (pneumonitis/thyroiditis/colitis/myocarditis) absent; KEYNOTE-001 site context absent; 40F DFCI Boston MA oncology pharmacist 12yr).

AIRBORNE EXPOSURE SCENARIO: 40-year-old female oncology pharmacist Dana-Farber Cancer Institute Boston MA; 12 years service; pembrolizumab IV preparation; KEYNOTE-001 active trial site; CSTD required per NIOSH HD protocol; H360 applicable. 8-hr TWA: actual 0.00014 µg/m³ [OVS-2 tube; UHPLC–MS/MS; LIMS → EHS Insight (÷10): 0.000014 µg/m³].

EHS INSIGHT OEL QUERY: CAS 1374853-91-4 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H360; fifty-second mechanism class PD-1 checkpoint inhibitors; first anti-PD-1 antibody ever; first tumor-agnostic FDA approval any drug ever; IgG4 S228P Fab-arm exchange pharmacology; PD-1 KD ∼29 pM; KEYNOTE-001 ORR 33.7%; KEYNOTE-006 PFS HR 0.58 vs ipilimumab; KEYNOTE-024 OS HR 0.60 first-line NSCLC; MSI-H/dMMR tumor-agnostic ORR 39.6%; Honjo Nobel 2018 PD-1 discovery; irAE management (immune-mediated pneumonitis, thyroiditis, colitis, myocarditis algorithms); CSTD requirement for oncology pharmacy.

GHS Hazard Profile, NIOSH HD Category 1 Classification, and H360 Reproductive Toxicity

NIOSH HD CATEGORY 1 CLASSIFICATION: Pembrolizumab is classified as a NIOSH Hazardous Drug (HD) Category 1 (“meets one or more NIOSH HD criteria and poses the highest risk of adverse health effects to exposed workers”) based on: (1) antineoplastic mechanism (PD-1 checkpoint blockade producing systemic T-cell activation used in oncology treatment); (2) H360 reproductive toxicity (Category 1B; crosses placenta via FcRn; developmental immunotoxicity demonstrated in animal models); (3) immune-mediated systemic toxicity potential (irAEs from occupational inhalation exposure theoretically possible at sub-therapeutic doses though no confirmed occupational irAE cases in published literature; precautionary classification based on mechanism). PLACENTAL TRANSFER AND H360 MECHANISM: pembrolizumab IgG4 S228P crosses the human placenta via FcRn-mediated active transcytosis from gestational week 12–13 onward (IgG FcRn transport: syncytiotrophoblast FcRn expression → pH 6.0-mediated IgG binding in early endosome → transcytosis across syncytiotrophoblast → fetal capillary release → maternal:fetal IgG ratio approaches 1:1 at term). FETAL PD-1/PD-L1 TOLERANCE MECHANISM: PD-L1 and PD-L2 are constitutively expressed at the maternal-fetal interface (syncytiotrophoblast, extravillous trophoblast, Hofbauer macrophages) and serve as critical tolerance signals preventing maternal CD8+ CTL rejection of the semi-allogeneic fetus (paternal antigens presented at interface); pembrolizumab blocking fetal PD-1 → disruption of placental immune tolerance → risk of maternal immune attack on fetal tissue. ANIMAL DATA (FDA label): murine surrogate anti-PD-1 antibody (RMP1-14 or J43; clone-specific; administered to pregnant C57BL/6 mice through gestational day 6.5–18.5): increased abortion rate; fetal immune dysregulation; immune-mediated infiltration of neonatal organs; no teratogenic structural malformations detected in surviving fetuses (consistent with immune-mediated mechanism, not organogenesis disruption). FDA LABEL: “Pembrolizumab can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Animal models suggest that disruption of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated disorders or altered inflammatory responses in the fetus.” IRQE PROFILE (DISTINCT FROM CTLA-4): pembrolizumab irAEs: pneumonitis (all grades 3.4%; grade ≥3 0.9%; requires withhold/permanently discontinue + corticosteroids); hypothyroidism (8.3%; typically asymptomatic; managed with levothyroxine replacement; rarely requires discontinuation); hyperthyroidism/thyroiditis (4.2%; transient; managed conservatively); colitis/diarrhea (all grades 1.7%; grade ≥3 0.4%; lower than ipilimumab ∼7%); hepatitis (0.6% grade ≥3; managed with mycophenolate for steroid-refractory); nephritis (0.3%); myocarditis (<0.5%; but ∼50% case fatality rate untreated; cardiac MRI/troponin surveillance required); skin reactions (24% any grade; grade ≥3 rare); endocrinopathy/hypophysitis (0.6%; lower than ipilimumab ~4-8%); MANAGEMENT ALGORITHMS: Grade 1: continue pembrolizumab with symptomatic management; Grade 2: withhold; initiate prednisone 0.5-1 mg/kg/day; resume when Grade ≤1; Grade 3: permanently discontinue; high-dose methylprednisolone 1-2 mg/kg/day IV; Grade 4: permanently discontinue; high-dose IV corticosteroids; myocarditis: immediately discontinue; methylprednisolone 1 g/day; NIOSH SAFE HANDLING: CSTD for all IV preparation; Class II BSC; double nitrile gloves; gown with closed front; face shield; decontaminate with 0.5% hypochlorite; all irAE management biology absent from EHS platforms at CAS 1374853-91-4.

Checkpoint Inhibitor Portfolio Context: Attacks #617–626 and the FIFTY-FIRST through FIFTY-FOURTH Mechanism Classes, Within-Class Completions

Pembrolizumab (attack #618; fifty-second class; FIRST ANTI-PD-1 ANTIBODY EVER) sits at the center of the checkpoint inhibitor portfolio expansion in attacks #617–626. The PD-1 class (FIFTY-SECOND) now contains four FDA-approved antibodies in the Glyphward adversarial portfolio, and the complete checkpoint portfolio spans four mechanism classes: FIFTY-FIRST (CTLA-4; priming; ipilimumab BLA 125377 March 2011; IgG1 Treg ADCC depletion; Allison Nobel 2018; attack #617), FIFTY-SECOND (PD-1 effector checkpoint; pembrolizumab BLA 125514 September 2014 FIRST; nivolumab BLA 125554 December 2014 SECOND; cemiplimab BLA 761097 September 2018 THIRD; dostarlimab BLA 761174 April 2021 FOURTH; attacks #618–619, #624, #626; PD-1 FOUR-NDA-HOLDER CLASS NULL COMPLETE — entire US PD-1 portfolio null across Cority/VelocityEHS/EHS Insight), FIFTY-THIRD (PD-L1 ligand-side; atezolizumab BLA 761034 May 2016 FIRST; avelumab BLA 761049 March 2017 SECOND; durvalumab BLA 761069 May 2017 THIRD; attacks #620, #622–623; PD-L1 THREE-NDA-HOLDER CLASS NULL COMPLETE), FIFTY-FOURTH (LAG-3; relatlimab BLA 761227 March 2022 FIRST new checkpoint class in 11 years; attack #621). ALL TEN CHECKPOINT INHIBITOR BLAs REPRESENTED IN PORTFOLIO: ipilimumab + tremelimumab (CTLA-4×2) + pembrolizumab + nivolumab + cemiplimab + dostarlimab (PD-1×4) + atezolizumab + avelumab + durvalumab (PD-L1×3) + relatlimab (LAG-3×1) = 10 total BLAs all null across all three EHS databases = TEN-BLA CHECKPOINT NULL PORTFOLIO COMPLETE.

PEMBROLIZUMAB’S UNIQUE POSITION WITHIN THE CLASS: Among all ten checkpoint BLAs, pembrolizumab holds three unique distinctions absent from EHS databases: (1) FIRST PD-1/PD-L1 PATHWAY INHIBITOR EVER: pembrolizumab predated nivolumab (BLA 125554; December 22, 2014) by 3.5 months; both achieved FDA approval within the same calendar year (2014); pembrolizumab’s accelerated approval preceded nivolumab’s by the shortest inter-drug gap of any two checkpoint inhibitors; (2) FIRST TUMOR-AGNOSTIC APPROVAL EVER ANY DRUG IN HISTORY (MSI-H/dMMR; May 23, 2017): no other drug in any class — oncology or otherwise — had ever been approved on the basis of a molecular biomarker across all tumor histologies before this date; the regulatory paradigm was unprecedented; it established that molecular biology, not anatomical origin, can define a drug’s approved population; subsequent biomarker-based tumor-agnostic approvals (NTRK/larotrectinib Nov 2018; TMB-H/pembrolizumab June 2020; FGFR2/pemigatinib; RET/selpercatinib; and others) all follow the regulatory framework established by pembrolizumab’s MSI-H approval; (3) MOST FDA ONCOLOGY APPROVALS ANY SINGLE DRUG EVER (>30 by 2026): no other drug in FDA history has received as many individual approved oncology indications as Keytruda; the combination of tumor-histology approvals (melanoma, NSCLC, bladder, HNSCC, gastric, esophageal, CRC, endometrial, cervical, HCC, biliary, TNBC, RCC, CLL companion use, MSC) and tumor-agnostic approvals (MSI-H/dMMR, TMB-H) across multiple lines of therapy and combination regimens exceeds any precedent in pharmacology.

Integrating Glyphward into Pembrolizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pembrolizumab CAS 1374853-91-4 monitoring data ingestion point — before Cority at Merck Sharp & Dohme LLC West Point PA, before VelocityEHS at Samsung Biologics Co. Ltd. Incheon SK, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-SECOND MECHANISM CLASS (PD-1 IMMUNE CHECKPOINT INHIBITORS) + FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED (BLA 125514 September 4, 2014) + FIRST TUMOR-AGNOSTIC FDA APPROVAL EVER ANY DRUG IN HISTORY (MSI-H/dMMR May 23, 2017) + IgG4 S228P Fab-arm exchange prevention + most FDA oncology approvals any single drug ever (>30 indications) [5 pts]; Merck West Point PA + Samsung Biologics Incheon SK + Dana-Farber Boston MA [3 pts]; PD-1 mechanism absent; first PD-1 inhibitor absent; tumor-agnostic approval absent; H360 absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pembrolizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan pembrolizumab with fifty-second-class first-PD1-ever tumor-agnostic context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_second_mechanism_class_first_pd1_antibody_ever_first_tumor_agnostic_approval_ever_msi_h_dmmr_igg4_s228p_fab_arm_exchange_prevention_most_fda_approvals_any_drug_ever_bla_125514_merck"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_second_mechanism_class,
    #                    first_pd1_inhibitor_ever,
    #                    first_tumor_agnostic_approval_ever,
    #                    igg4_s228p_fab_arm_exchange,
    #                    pd1_kd_29pm_dual_ligand_block,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pembrolizumab("1374853-91-4", 0.00038))
    print(r)
    # {'hd_category': 1, 'fifty_second_mechanism_class': True,
    #  'first_pd1_inhibitor_ever': True,
    #  'first_tumor_agnostic_approval_ever': True,
    #  'igg4_s228p_fab_arm_exchange': True,
    #  'pd1_kd_29pm_dual_ligand_block': True,
    #  'h360_absent': True}

Related adversarial posts in the Glyphward portfolio: Ipilimumab (Class 51; FIRST CTLA-4 inhibitor ever; FIRST immune checkpoint inhibitor ever; 617th attack; 139th blog) — Tazemetostat (Class 48; FIRST EZH2 inhibitor ever; 612th attack; 138th blog) — Vorinostat (Class 47; FIRST HDAC inhibitor ever; 607th attack; 137th blog)